BioSpace News Archive

Researchers have genetically engineered the first mice that get a human-like form of COVID-19, according to a study published online November 1 in Nature.

scPharmaceuticals Inc. announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 8, 2023, to discuss the financial results for the third quarter 2023 and provide a business update.

Spero Therapeutics, Inc. announced that Sath Shukla, President and Chief Executive Officer, will be available for one-on-one meetings at the Truist Securities BioPharma Symposium, to be held at the Lotte New York Palace in New York, NY, on November 8-9, 2023 and will present and be available for one-on-one meetings at the 6th Annual Evercore ISI HealthCONx Conference to be held at the Kimpton EPIC Miami Hotel in Miami, FL, on November 28-30, 2023.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced that management will participate in three upcoming investor conferences in November.

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2023.

Cytokinetics, Incorporated announced that the company is scheduled to participate in the following investor conferences in November:

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on U.S. Phase 1 NX-2127-001 study evaluating NX-2127 in various B-cell malignancies.

X4 Pharmaceuticals, a company driven to improve the lives of people with rare diseases of the immune system, announced that, effective on October 31, 2023, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2023 financial and operating results after the close of U.S. financial markets on Wednesday, November 8, 2023.

Aadi Bioscience, Inc. (NASDAQ: AADI) today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023 at 8:30 am ET (5:30 am PT) to report third quarter 2023 financial results and provide an operational update.